Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis by Robertson, Jamie et al.
  
 
 
 
 
Robertson, J., Porter, D., Sattar, N., Packard, C. J., Caslake, M., McInnes, I. and 
McCarey, D. (2017) Interleukin-6 blockade raises LDL via reduced catabolism rather 
than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in 
rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(11), pp. 1949-1952. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/148846/ 
     
 
 
 
 
 
 
Deposited on: 11 October 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
"Interleukin-6 Blockade Raises LDL Via Reduced Catabolism Rather 
Than Via Increased Synthesis – A Cytokine-Specific Mechanism For 
Cholesterol Changes In Rheumatoid Arthritis" 
 
Jamie Robertson1, Duncan Porter2, Naveed Sattar3, Chris Packard3, Muriel Caslake3, Iain McInnes*1, 
David McCarey*4 
1. Institute of Infection, Immunity & Inflammation, University of Glasgow 
2.  Gartnavel General Hospital, Glasgow, UK 
3. Institute of Cardiovascular & Medical Sciences, University of Glasgow 
4. Glasgow Royal Infirmary, Glasgow, UK 
* denotes co-senior authors. 
Corresponding author –  
Dr Jamie Robertson 
University of Glasgow, Institute of Infection, Immunity & Inflammation 
Sir Graeme Davies Building 
120 University Place 
Glasgow, UK G12 8TA 
jamiesummersrobertson@gmail.com 
Keywords: Rheumatoid arthritis; cytokines; lipids; cardiovascular disease 
 
  
Abstract 
 
Objectives: Patients with rheumatoid arthritis (RA) have reduced serum LDL-cholesterol (LDL-c), 
which increases following therapeutic IL-6 blockade.   We aimed to define the metabolic pathways 
underlying these lipid changes. 
Methods: In the KALIBRA study, lipoprotein kinetic studies were performed on 11 patients with 
severe active RA at baseline and following three I.V. infusions of the IL-6R blocker Tocilizumab.   The 
primary outcome measure was the fractional catabolic rate (FCR) of LDL.    
Results: Serum total cholesterol (4.8 v 5.7mmol/L, p=0.003), LDL-c (2.9 v 3.4mmol/l, p=0.014) and 
HDL-c (1.23 v 1.52mmol/L, p=0.006) increased following Tocilizumab therapy.  The LDL FCR fell from 
a state of hypercatabolism to a value approximating that of the normal population (0.53 v 0.27 
pools/day, p=0.006).   Changes in FCR correlated tightly with changes in serum LDL-c and CRP but not 
CDAI. 
Conclusions: RA patients have low serum LDL-c due to hypercatabolism of LDL particles.   IL-6 
blockade normalises this catabolism in a manner associating with the acute phase response (and 
thus hepatic IL-6 signalling) but not with RA disease activity as measured clinically.   We demonstrate 
that IL-6 is one of the key drivers of inflammation-driven dyslipidaemia. 
 
  
Introduction 
 
Patients with rheumatoid arthritis (RA) have serum low-density lipoprotein cholesterol (LDL-c) levels 
lower than those of age-and sex-matched controls (1-3), despite also having an approximately 50% 
greater risk of developing cardiovascular disease (CVD) (4, 5).   Conversely, increases in LDL-c or LDL 
particle numbers have also been observed following treatment of RA with the interleukin-6 (IL-6) 
receptor blocker Tocilizumab (6-8) and the janus kinase (JAK) inhibitors (9).   The mechanisms 
underlying this so-called “lipid-paradox”, and the influence of therapy-driven LDL-c changes on 
cardiovascular risk, remain only partially understood(10).    
Reduced serum LDL-c might be due to reduced LDL synthesis (predominantly from lipolysis of very 
low-density lipoprotein [VLDL] and intermediate-density lipoprotein [IDL])   or increased LDL 
turnover.   Hypercatabolism of LDL has previously been identified in hypertrigliceridaemic patients, 
with catabolic ratesnormalising following reduction of serum TG with fibrates(11).   
Tocilizumab is an established and effective treatment for RA which has been shown to increase LDL-c 
by up to 20% on average (7).   We therefore hypothesised that Tocilizumab would reduce LDL 
catabolism and thus increase serum LDL-c in patients with active RA. 
 
Methods 
 
In the KALIBRA study (Kinetics of the ApoB-containing Lipoproteins in IL-6 Blockade for RA) we 
performed kinetic studies on patients with active RA before and after ten weeks’ treatment with 
Tocilizumab.   The primary outcome measure was the change in fractional catabolic rate (FCR) of 
LDL-associated ApoB. 
 Recruitment 
Subjects were recruited from rheumatology clinics in Glasgow, UK.   Patients were provided with 
information on the study for at least 48 hoursbefore a screening visit where written, informed 
consent was provided.   All further assessments took place at the Clinical Research Facility (CRF) of 
the Western Infirmary Glasgow.   Subjects met the following inclusion criteria: RA (2010 ACR 
criteria); DAS28≥5.1; failure of two conventional DMARDS, including methotrexate; and suitability 
for tocilizumab therapy.   Exclusion criteria included: familial dyslipidaemia; ApoE 2/2 homozygosity; 
diabetes mellitus; use of lipid-lowering therapeutics; fasting TC  ≥6.5mmol/L; fasting TG ≥3mmol/L; 
pregnancy; or untreated hypothyroidism.   Use of oral steroid was permitted at a steady dose, but 
parenteral corticosteroid  was prohibited. 
Ethical approval for the KALIBRA study was granted locally by the West of Scotland Research Ethics 
Committee. 
Kinetic studies 
Each subject underwent a kinetic study at baseline, followed by at least 10 weeks (i.e. three 
infusions) of Tocilizumab 8mg/kg IV, and a subsequent “on-treatment” kinetic study. 
In each kinetic study, a tracer in the form of the stable isotope d3-leucine at 10mg/kg body weight 
bolus was administered.   Leucine is taken up by hepatocytes and incorporated into apoB.    Fasting 
blood samples were obtained at 23 timepoints over 96 hours.   Density-gradient ultracentrifugation, 
precipitation and gas chromatography mass spectrometry (GCMS) could then be used to determine 
the tracer/tracee ratio in all the apoB-containing lipoproteins at each timepoint.    A 15-
compartment mathematical model was used to analyse the the lipolytic pathway through VLDL1, 
VLDL2, IDL and LDL.   SAAM software was then employed to calculate the production rate (PR) and 
fractional catabolic rate (FCR) of LDL. 
Sample handling & processing 
At each kinetic study, blood samples were obtained for beta-quantification of lipids; CRP and ESR; 
Lp(a); insulin; PCSK9 levels; apolipoproteins by immunoturbidimetry; and activity of CETP and 
heparin-inducible lipasesDAS28 and CDAI were assessed by a clinical research fellow in 
rheumatology.    
Statistical analyses 
Statistical analysis was performed at the Robertson Centre for Biostatistics, University of Glasgow.   
Pre- and post-treatment analyses were performed using paired t-test or Wilcoxon matched-pairs 
test.   Correlations were performed using Spearman’s r, due to the high prevalence of non-
parametric data. 
In normal subjects, the FCR of LDL-associated apoB is around 0.3 pools per day.   In those with 
increased catabolism due to hypertriglyceridemia in a previous study, the FCR is around 0.5 pools 
per day; this corresponded to a large decrease in LDL-c of around 1.5mmol/l (12).   In contrast, 
ciprofibrate has been shown to increase LDL FCRfrom 0.32 to 0.38 pools per day, with a 22% fall in 
LDL-c (13). This is similar LDL-c changes seen following tocilizumab therapy, and reflects a 
biologically significant change in FCR.    Using these figures, we used a conservative change in FCR of 
around 0.05 pools per day to determine power.   A sample size of 15 subjects allows us to detect a 
difference in fractional catabolic rate of 0.05 with SD 0.05 at 90% power and alpha error at 5%. This 
sample size is typical for kinetic trials of this type. 
Reagent supply 
D3-Leucine was prepared by Tayside Pharmaceuticals Ltd, Dundee, UK.   Tocilizumab for this study 
was graciously provided by Roche Products Ltd 
 
Results 
 
Demographics 
Twelve subjects were recruited (Table 1).   One subject withdrew before their second kinetic study, 
leaving useable data for eleven subjects.    
Clinical response 
At baseline, mean DAS28-CRP and CDAI were 5.16 and 29.9 respectively.   Changes in parameters of 
disease activity are summarised in  the online supplementary figure S1.   After treatment, seven 
subjects were in DAS28 remission, whilst one met the criteria for CDAI remission. 
Serum cholesterol  
Beta-quantification of serum lipids is shown in online supplementary table S1.   Elevations were 
observed in TC, LDL-c and HDL-c.   No change was seen in the TC/HDL-c ratio. 
LDL kinetics 
Production and catabolic rates for LDL are displayed in Figure 1.  Median (IQR) FCR, the primary 
outcome measure for the study, fell from 0.53 (0.32-0.68) pools/day to 0.27 (0.19-0.37) pools/day 
(p=0.002), with median change from baseline of -30%.   LDL PR also fell significantly, with reduced 
apoB transfer from VLDL-2 through IDL to LDL.   
LDL FCR associated strongly with LDL-c both at baseline and in degree of change from baseline 
(Figure 2A).   At baseline, FCR correlated with CRP (r=0.74, p=0.012) and showed a non-significant 
trend to association with ESR (r=0.54, p=0.091).   However, FCR did not associate at all with clinical 
assessment of disease activity, as measured by CDAI (r=0.04, p=0.91) (Figure 2B).   Similar, non-
significant trends were seen in degree of change for FCR versus CRP (r=0.46, p=0.15), ESR (r=0.30, 
p=0.37) and CDAI (r=-0.37, p=0.26)  
Secondary outcomes 
Serum Lp(a) fell, whilst ApoAI, ApoAII, and ApoB increased.   Activity levels of CETP, lipoprotein 
lipase, and hepatic lipase, and serum levels of insulin or PCSK9, did not change (online 
supplementary table S2). 
Safety 
Two serious adverse events were reported.  One patient developed a subcutaneous abscess;; this 
was successfully treated, and the patient resumed therapy and completed the study.   Another 
patient developed paronychia and withdrew from the study. 
 
Discussion 
 
KALIBRA is the first study to demonstrate increased catabolism of LDL particles in active RA.   This 
hypercatabolism correlates tightly with serum LDL-c and acute phase reactants but not with clinical 
measures of RA activity, and normalises following IL-6 blockade with tocilizumab.   Tocilizumab also 
reduced LDL production, though this appears to be of negligible biochemical significance as LDL-c 
ultimately increased. 
These findings allow us to draw some conclusions.   Firstly, IL-6 appears to be a key driver of LDL 
change in RA.   We surmise this from tocilizumab’s mechanism of action, but also from the 
association of LDL kinetics ith the acute phase response (driven by IL-6) rather than clinical disease 
activity; hence, hepatic IL-6 signalling, rather than synovitic bulk, might lie behind LDL changes.   
Finally, these results are reassuring in terms of the safety of IL-6 blockade, as normalisation of 
pathological LDL hypercatabolism seems unlikely to drive new atheroma formation.    
Charles-Schoeman et al previously performed lipid kinetic studies in 33 RA subjects before and after 
6 weeks of treatment with tofacitinib, a Janus kinase (JAK) inhibitor, and 31 healthy volunteers (14).   
This cohort had increased catabolism of cholesterol ester (but not LDL-associated ApoB) at baseline, 
which was reduced by tofacitinib.   The authors hypothesised decreasing process of reduced hepatic 
HDL clearance, with LDL then gaining cholesterol via CETP, reflecting a potentially different 
mechanism to our own observations. 
We believe that KALIBRA holds some advantages over this earlier work.   Firstly, using tocilizumab 
allows us to identify IL-6 as the key molecule behind our results.   Tofacitinib, as an inhibitor of 
multiple JAKs (and thus many upstream cytokines), cannot provide such precise mechanistic 
information.   Secondly, all our patients had severe active RA with DAS28≥5.1.   This makes our 
results more relevant to clinical practice, and gives greater scope for detectable inflammation-driven 
pathology (and subsequent detectable reversal of that pathology).   Charles-Schoeman did not 
provide values for DAS28, CDAI, ESR or CRP, though the inclusion criteria seem to indicate lower 
disease activity than our own cohort.   Thirdly, our collection of clinical data pre- and post-treatment 
allowed us to ascertain clinical response to the drug, and correlate this with metabolic changes.    
Our study has some important limitations.   The small sample size, whilst in keeping with previous 
such kinetic studies, limited our ability to analyse secondary outcome data.   Local technical 
limitations precluded a control group; however, the magnitude of kinetic changes observed are close 
to previously-described population values of hypercatabolism (at baseline) and normal metabolism 
(post-treatment).   
In conclusion, we demonstrate for the first time that serum LDL-c levels are reduced in active RA due 
to abnormally elevated LDL catabolism.   Additionally, we show that this hypercatabolic state is 
exquisitely linked to IL-6 signalling, and normalises following therapeutic IL-6 blockade regardless of 
any clinical reduction in disease activity. 
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Tables 
 
 Mean (%) 
Age 49.9 
Sex (F) 10 (83%) 
RF / CCP + 10 (83%) 
Methotrexate 4 (33%) 
Other DMARD 8 (67%) 
Prednisolone 2 (17%) 
NSAID 8 (67%) 
Previous Biologic 
therapy 
3 (25%) 
 
Table 1. Demographic data of KALIBRA subjects at baseline.  N=12. 
 
 
Figure 1. Changes in LDL production rate and FCR after treatment with tocilizumab (N=11). P value 
generated by Wilcoxon matched-pairs test. FCR,fractional catabolic rate; LDL, low-density 
lipoprotein. 
 Figure 2.   (A) Correlations of LDL FCR with LDL-c at baseline (left) and in degree of change (right). (B) 
Correlations of LDL FCR with markers of RA disease activity. N=11. R and p values calculated by 
Spearman’s r test. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; FCR, fractional catabolic rate; LDL-c, low-density lipoprotein cholesterol; RA, 
rheumatoid arthritis. 
